
|Videos|November 12, 2018
Quadruplet Versus Triplet Regimens in Multiple Myeloma
Author(s)Sarah Holstein, MD, PhD
Sarah Holstein, MD, PhD, explains her rationale for choosing a triplet regimen over a quadruplet in patients with multiple myeloma.
Advertisement
Sarah Holstein, MD, PhD, associate professor at the University of Nebraska Medical Center, explains her rationale for choosing a triplet regimen over a quadruplet in patients with multiple myeloma.
Holstein does not use quadruplet regimens outside of clinical trials because the treatment paradigm is not quite there, she says. However, she tries to use triplet combinations in the majority of her patients.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5








































